Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $1.28 Analyst target: $14.00 Upside: 993.75%
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company is headquartered in Alpharetta, Georgia.
See the full interactive analysis & chart →Informational only — not investment advice.